Agnes Viale

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/11628942/publications.pdf

Version: 2024-02-01

105 papers	34,180 citations	12322 69 h-index	27389 106 g-index
107 all docs	107 docs citations	107 times ranked	51730 citing authors

#	Article	IF	Citations
1	The Somatic Genomic Landscape of Glioblastoma. Cell, 2013, 155, 462-477.	13.5	3,979
2	Genes that mediate breast cancer metastasis to lung. Nature, 2005, 436, 518-524.	13.7	2,581
3	Prognostic Relevance of Integrated Genetic Profiling in Acute Myeloid Leukemia. New England Journal of Medicine, 2012, 366, 1079-1089.	13.9	1,688
4	IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype. Nature, 2012, 483, 479-483.	13.7	1,668
5	MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 20932-20937.	3.3	1,557
6	Precision microbiome reconstitution restores bile acid mediated resistance to Clostridium difficile. Nature, 2015, 517, 205-208.	13.7	1,506
7	Gene expressionâ€"based survival prediction in lung adenocarcinoma: a multi-site, blinded validation study. Nature Medicine, 2008, 14, 822-827.	15.2	1,015
8	Modelling pathogenesis and treatment of familial dysautonomia using patient-specific iPSCs. Nature, 2009, 461, 402-406.	13.7	808
9	Intestinal Domination and the Risk of Bacteremia in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation. Clinical Infectious Diseases, 2012, 55, 905-914.	2.9	779
10	Vancomycin-resistant Enterococcus domination of intestinal microbiota is enabled by antibiotic treatment in mice and precedes bloodstream invasion in humans. Journal of Clinical Investigation, 2010, 120, 4332-4341.	3.9	756
11	The effects of intestinal tract bacterial diversity on mortality following allogeneic hematopoietic stem cell transplantation. Blood, 2014, 124, 1174-1182.	0.6	711
12	Recurrent somatic TET2 mutations in normal elderly individuals with clonal hematopoiesis. Nature Genetics, 2012, 44, 1179-1181.	9.4	692
13	Genome Sequencing Identifies a Basis for Everolimus Sensitivity. Science, 2012, 338, 221-221.	6.0	681
14	Germline mutations in BAP1 predispose to melanocytic tumors. Nature Genetics, 2011, 43, 1018-1021.	9.4	662
15	Chromatin states define tumour-specific T cell dysfunction and reprogramming. Nature, 2017, 545, 452-456.	13.7	643
16	Subtype-specific genomic alterations define new targets for soft-tissue sarcoma therapy. Nature Genetics, 2010, 42, 715-721.	9.4	642
17	The Genomic Landscape of Endocrine-Resistant Advanced Breast Cancers. Cancer Cell, 2018, 34, 427-438.e6.	7.7	633
18	Clinical Sequencing Defines the Genomic Landscape of Metastatic Colorectal Cancer. Cancer Cell, 2018, 33, 125-136.e3.	7.7	589

#	Article	IF	Citations
19	^{V600E} BRAF is associated with disabled feedback inhibition of RAFâ€“MEK signaling and elevated transcriptional output of the pathway. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 4519-4524.	3.3	535
20	Profound Alterations of Intestinal Microbiota following a Single Dose of Clindamycin Results in Sustained Susceptibility to Clostridium difficile-Induced Colitis. Infection and Immunity, 2012, 80, 62-73.	1.0	473
21	Optimization of Dosing for EGFR-Mutant Nonâ€“Small Cell Lung Cancer with Evolutionary Cancer Modeling. Science Translational Medicine, 2011, 3, 90ra59.	5.8	457
22	The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 14903-14908.	3.3	417
23	Periodontal disease and the oral microbiota in newâ€onset rheumatoid arthritis. Arthritis and Rheumatism, 2012, 64, 3083-3094.	6.7	399
24	The mutational landscape of adenoid cystic carcinoma. Nature Genetics, 2013, 45, 791-798.	9.4	394
25	Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes. Nature Medicine, 2020, 26, 1549-1556.	15.2	372
26	Tracking tumour evolution in glioma through liquid biopsies of cerebrospinal fluid. Nature, 2019, 565, 654-658.	13.7	361
27	Relief of Feedback Inhibition of HER3 Transcription by RAF and MEK Inhibitors Attenuates Their Antitumor Effects in BRAF-Mutant Thyroid Carcinomas. Cancer Discovery, 2013, 3, 520-533.	7.7	328
28	Ibrutinib Unmasks Critical Role of Bruton Tyrosine Kinase in Primary CNS Lymphoma. Cancer Discovery, 2017, 7, 1018-1029.	7.7	302
29	Evaluating Cancer of the Central Nervous System Through Next-Generation Sequencing of Cerebrospinal Fluid. Journal of Clinical Oncology, 2016, 34, 2404-2415.	0.8	297
30	Comparative sequencing analysis reveals high genomic concordance between matched primary and metastatic colorectal cancer lesions. Genome Biology, 2014, 15, 454.	3.8	296
31	Familial transmission rather than defective innate immunity shapes the distinct intestinal microbiota of TLR-deficient mice. Journal of Experimental Medicine, 2012, 209, 1445-1456.	4.2	295
32	Tumour lineage shapes BRCA-mediated phenotypes. Nature, 2019, 571, 576-579.	13.7	295
33	Prevalence and Co-Occurrence of Actionable Genomic Alterations in High-Grade Bladder Cancer. Journal of Clinical Oncology, 2013, 31, 3133-3140.	0.8	282
34	Genomic safe harbors permit high Î²-globin transgene expression in thalassemia induced pluripotent stem cells. Nature Biotechnology, 2011, 29, 73-78.	9.4	277
35	Genome-wide association study provides evidence for a breast cancer risk locus at 6q22.33. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 4340-4345.	3.3	274
36	Molecular International Prognostic Scoring System for Myelodysplastic Syndromes. , 2022, 1, .		259

#	Article	IF	Citations
37	Comparative Genomic Analysis of Primary Versus Metastatic Colorectal Carcinomas. Journal of Clinical Oncology, 2012, 30, 2956-2962.	0.8	254
38	Breast Cancer Methylomes Establish an Epigenomic Foundation for Metastasis. Science Translational Medicine, 2011, 3, 75ra25.	5.8	242
39	Gene Expression Profiling of Liposarcoma Identifies Distinct Biological Types/Subtypes and Potential Therapeutic Targets in Well-Differentiated and Dedifferentiated Liposarcoma. Cancer Research, 2007, 67, 6626-6636.	0.4	217
40	Multi-platform assessment of transcriptome profiling using RNA-seq in the ABRF next-generation sequencing study. Nature Biotechnology, 2014, 32, 915-925.	9.4	217
41	Efficient induction of differentiation and growth inhibition in IDH1 mutant glioma cells by the DNMT Inhibitor Decitabine. Oncotarget, 2013, 4, 1729-1736.	0.8	213
42	Tumor Genetic Analyses of Patients with Metastatic Renal Cell Carcinoma and Extended Benefit from mTOR Inhibitor Therapy. Clinical Cancer Research, 2014, 20, 1955-1964.	3.2	208
43	Identification of kinase fusion oncogenes in post-Chernobyl radiation-induced thyroid cancers. Journal of Clinical Investigation, 2013, 123, 4935-4944.	3.9	197
44	Mutational Cooperativity Linked to Combinatorial Epigenetic Gain of Function in Acute Myeloid Leukemia. Cancer Cell, 2015, 27, 502-515.	7.7	191
45	Hotspot activating PRKD1 somatic mutations in polymorphous low-grade adenocarcinomas of the salivary glands. Nature Genetics, 2014, 46, 1166-1169.	9.4	188
46	Classification of Clear-Cell Sarcoma as a Subtype of Melanoma by Genomic Profiling. Journal of Clinical Oncology, 2003, 21, 1775-1781.	0.8	177
47	Epigenetic expansion of VHL-HIF signal output drives multiorgan metastasis in renal cancer. Nature Medicine, 2013, 19, 50-56.	15.2	174
48	Genomic Biomarkers of a Randomized Trial Comparing First-line Everolimus and Sunitinib in Patients with Metastatic Renal Cell Carcinoma. European Urology, 2017, 71, 405-414.	0.9	173
49	Massively Parallel Sequencing-Based Clonality Analysis of Synchronous Endometrioid Endometrial and Ovarian Carcinomas. Journal of the National Cancer Institute, 2015, 108, djv427.	3.0	164
50	Phase 1b trial of an ibrutinib-based combination therapy in recurrent/refractory CNS lymphoma. Blood, 2019, 133, 436-445.	0.6	159
51	A recurrent neomorphic mutation in MYOD1 defines a clinically aggressive subset of embryonal rhabdomyosarcoma associated with PI3K-AKT pathway mutations. Nature Genetics, 2014, 46, 595-600.	9.4	152
52	Pan-cancer genetic analysis identifies PARK2 as a master regulator of G1/S cyclins. Nature Genetics, 2014, 46, 588-594.	9.4	144
53	Frequent somatic CDH1 loss-of-function mutations in plasmacytoid variant bladder cancer. Nature Genetics, 2016, 48, 356-358.	9.4	143
54	Isoform Switching as a Mechanism of Acquired Resistance to Mutant Isocitrate Dehydrogenase Inhibition. Cancer Discovery, 2018, 8, 1540-1547.	7.7	138

#	Article	IF	Citations
55	Gene Expression Profiling Allows Distinction between Primary and Metastatic Squamous Cell Carcinomas in the Lung. Cancer Research, 2005, 65, 3063-3071.	0.4	132
56	Interlaboratory comparability study of cancer gene expression analysis using oligonucleotide microarrays. Clinical Cancer Research, 2005, 11, 565-72.	3.2	125
57	CHZ868, a Type II JAK2 Inhibitor, Reverses Type I JAK Inhibitor Persistence and Demonstrates Efficacy in Myeloproliferative Neoplasms. Cancer Cell, 2015, 28, 15-28.	7.7	124
58	Synthetic Lethality in ATM-Deficient RAD50-Mutant Tumors Underlies Outlier Response to Cancer Therapy. Cancer Discovery, 2014, 4, 1014-1021.	7.7	114
59	NF2 Loss Promotes Oncogenic RAS-Induced Thyroid Cancers via YAP-Dependent Transactivation of RAS Proteins and Sensitizes Them to MEK Inhibition. Cancer Discovery, 2015, 5, 1178-1193.	7.7	107
60	Small RNA Sequencing and Functional Characterization Reveals MicroRNA-143 Tumor Suppressor Activity in Liposarcoma. Cancer Research, 2011, 71, 5659-5669.	0.4	106
61	Identification of DOK genes as lung tumor suppressors. Nature Genetics, 2010, 42, 216-223.	9.4	105
62	Casein Kinase II Alpha Subunit and C1-Inhibitor Are Independent Predictors of Outcome in Patients with Squamous Cell Carcinoma of the Lung. Clinical Cancer Research, 2004, 10, 5792-5803.	3.2	103
63	Targeted massively parallel sequencing of angiosarcomas reveals frequent activation of the mitogen activated protein kinase pathway. Oncotarget, 2015, 6, 36041-36052.	0.8	103
64	The Rho GTPase Rnd1 suppresses mammary tumorigenesis and EMT by restraining Ras-MAPKÂsignalling. Nature Cell Biology, 2015, 17, 81-94.	4.6	97
65	The Oncogenic Action of NRF2 Depends on De-glycation by Fructosamine-3-Kinase. Cell, 2019, 178, 807-819.e21.	13.5	96
66	Genetic Heterogeneity in Therapy-NaÃ¯ve Synchronous Primary Breast Cancers and Their Metastases. Clinical Cancer Research, 2017, 23, 4402-4415.	3.2	91
67	Extreme Outlier Analysis Identifies Occult Mitogen-Activated Protein Kinase Pathway Mutations in Patients With Low-Grade Serous Ovarian Cancer. Journal of Clinical Oncology, 2015, 33, 4099-4105.	0.8	88
68	Epigenomic Reorganization of the Clustered Hox Genes in Embryonic Stem Cells Induced by Retinoic Acid. Journal of Biological Chemistry, 2011, 286, 3250-3260.	1.6	86
69	Small-Cell Carcinomas of the Bladder and Lung Are Characterized by a Convergent but Distinct Pathogenesis. Clinical Cancer Research, 2018, 24, 1965-1973.	3.2	85
70	BAC Transgenesis in Human Embryonic Stem Cells as a Novel Tool to Define the Human Neural Lineage. Stem Cells, 2009, 27, 521-532.	1.4	75
71	Efficacy of Intermittent Combined RAF and MEK Inhibition in a Patient with Concurrent BRAF- and NRAS-Mutant Malignancies. Cancer Discovery, 2014, 4, 538-545.	7.7	73
72	Stat3 Mediates Expression of Autotaxin in Breast Cancer. PLoS ONE, 2011, 6, e27851.	1.1	64

#	Article	IF	Citations
73	The melanin-concentrating hormone gene in human: flanking region analysis, fine chromosome mapping, and tissue-specific expression. Molecular Brain Research, 1997, 46, 243-255.	2.5	62
74	Coaltered Ras/B-raf and TP53 Is Associated with Extremes of Survivorship and Distinct Patterns of Metastasis in Patients with Metastatic Colorectal Cancer. Clinical Cancer Research, 2020, 26, 1077-1085.	3.2	62
75	Quantification of tumor-derived cell free DNA(cfDNA) by digital PCR (DigPCR) in cerebrospinal fluid of patients with BRAFV600 mutated malignancies. Oncotarget, 2016, 7, 85430-85436.	0.8	60
76	Performance of Severe Acute Respiratory Syndrome Coronavirus 2 Real-Time RT-PCR Tests on Oral Rinses and Saliva Samples. Journal of Molecular Diagnostics, 2021, 23, 3-9.	1.2	59
77	Effects of Leptin on Melanin-Concentrating Hormone Expression in the Brain of Lean and Obese Lep^{ob}/Lep^{ob} Mice. Neuroendocrinology, 1999, 69, 145-153.	1.2	58
78	Distinction of Desmoplastic Melanoma from Non-Desmoplastic Melanoma by Gene Expression Profiling. Journal of Investigative Dermatology, 2005, 124, 412-419.	0.3	58
79	Cellular Localization and Role of Prohormone Convertases in the Processing of Pro-melanin Concentrating Hormone in Mammals. Journal of Biological Chemistry, 1999, 274, 6536-6545.	1.6	53
80	Segmental Duplications in Euchromatic Regions of Human Chromosome 5: A Source of Evolutionary Instability and Transcriptional Innovation. Genome Research, 2003, 13, 369-381.	2.4	51
81	Metastatic Competence Can Emerge with Selection of Preexisting Oncogenic Alleles without a Need of New Mutations. Cancer Research, 2015, 75, 3713-3719.	0.4	48
82	SETER/PR: a robust 18-gene predictor for sensitivity to endocrine therapy for metastatic breast cancer. Npj Breast Cancer, 2019, 5, 16.	2.3	48
83	Lobular Carcinomas In Situ Display Intralesion Genetic Heterogeneity and Clonal Evolution in the Progression to Invasive Lobular Carcinoma. Clinical Cancer Research, 2019, 25, 674-686.	3.2	44
84	Remodeling of the Methylation Landscape in Breast Cancer Metastasis. PLoS ONE, 2014, 9, e103896.	1.1	43
85	Targeted next-generation sequencing of DNA regions proximal to a conserved GXGXXG signaling motif enables systematic discovery of tyrosine kinase fusions in cancer. Nucleic Acids Research, 2010, 38, 6985-6996.	6.5	39
86	Phase II Trial of Sorafenib in Patients with Chemotherapy Refractory Metastatic Esophageal and Gastroesophageal (GE) Junction Cancer. PLoS ONE, 2015, 10, e0134731.	1.1	38
87	Antitumor Activity of SNX-2112, a Synthetic Heat Shock Protein-90 Inhibitor, in MET-Amplified Tumor Cells with or without Resistance to Selective MET Inhibition. Clinical Cancer Research, 2011, 17, 122-133.	3.2	36
88	Plasma DNA-Based Molecular Diagnosis, Prognostication, and Monitoring of Patients With EWSR1 Fusion-Positive Sarcomas. JCO Precision Oncology, 2017, 2017, 1-11.	1.5	36
89	Frequent disruption of the RB pathway in indolent follicular lymphoma suggests a new combination therapy. Journal of Experimental Medicine, 2014, 211, 1379-1391.	4.2	32
90	c-MYC regulates mRNA translation efficiency and start-site selection in lymphoma. Journal of Experimental Medicine, 2019, 216, 1509-1524.	4.2	32

#	Article	IF	Citations
91	Analysis of genetic variation in Ashkenazi Jews by high density SNP genotyping. BMC Genetics, 2008, 9, 14.	2.7	31
92	Peripheral Circulating Tumor DNA Detection Predicts Poor Outcomes After Liver Resection for Metastatic Colorectal Cancer. Annals of Surgical Oncology, 2019, 26, 1824-1832.	0.7	31
93	Somatic mutations in leukocytes infiltrating primary breast cancers. Npj Breast Cancer, 2015, 1, 15005.	2.3	30
94	Structure and Expression of the Variant Melanin-Concentrating Hormone Genes: Only PMCHL1 Is Transcribed in the Developing Human Brain and Encodes a Putative Protein. Molecular Biology and Evolution, 2000, 17, 1626-1640.	3.5	26
95	Quantitative assessment of intragenic receptor tyrosine kinase deletions in primary glioblastomas: their prevalence and molecular correlates. Acta Neuropathologica, 2014, 127, 747-759.	3.9	26
96	Tumor fraction-guided cell-free DNA profiling in metastatic solid tumor patients. Genome Medicine, 2021, 13, 96.	3.6	26
97	17Î²-Estradiol regulation of melanin-concentrating hormone and neuropeptide-E-I contents in cynomolgus monkeys: a preliminary study. Peptides, 1999, 20, 553-559.	1.2	24
98	Leveraging Systematic Functional Analysis to Benchmark an In Silico Framework Distinguishes Driver from Passenger MEK Mutants in Cancer. Cancer Research, 2020, 80, 4233-4243.	0.4	18
99	EGFR-Mutant Lung Adenocarcinomas Treated First-Line with the Novel EGFR Inhibitor, XL647, Can Subsequently Retain Moderate Sensitivity to Erlotinib. Journal of Thoracic Oncology, 2012, 7, 434-442.	0.5	17
100	Genetic analysis of five children with essential thrombocytosis identified mutations in cancer-associated genes with roles in transcriptional regulation. Haematologica, 2016, 101, e237-e239.	1.7	17
101	Targeting eIF4A-Dependent Translation of KRAS Signaling Molecules. Cancer Research, 2021, 81, 2002-2014.	0.4	17
102	NRF2 Activation Confers Resistance to eIF4A Inhibitors in Cancer Therapy. Cancers, 2021, 13, 639.	1.7	13
103	Germ Cell Tumor Molecular Heterogeneity Revealed Through Analysis of Primary and Metastasis Pairs. JCO Precision Oncology, 2020, 4, 1307-1320.	1.5	9
104	Structure, Expression, and Evolution of the Variant MCH Gene in Primatesa. Annals of the New York Academy of Sciences, 1998, 839, 214-218.	1.8	1
105	Frequent 4EBP1 Amplification Induces Synthetic Dependence on FGFR Signaling in Cancer. Cancers, 2022, 14, 2397.	1.7	1